VENOUS THROMBOEMBOLISM IN NORTHEAST MELBOURNE, AUSTRALIA: EVALUATION OF EPIDEMIOLOGY, RISK FACTORS AND TREATMENT STRATEGIES IN THE WARFARIN ERA
EHA Library, Hui Yin Lim, 100925
RESULTS OF A PHASE 3 RANDOMIZED CONTROLLED STUDY EVALUATING THE EFFICACY AND SAFETY OF IDELALISIB (IDELA) IN COMBINATION WITH OFATUMUMAB (OFA) FOR PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
EHA Library, Timothy Dichiara, 101336
GADOLIN: PRIMARY RESULTS FROM A PHASE III STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE COMPARED WITH BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA
EHA Library, Laurie Sehn, 101340
PRELIMINARY PHASE II RESULTS OF ARA-C AND IDARUBICIN IN COMBINATION WITH SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND SELINEXOR (KPT-330) IN PATIENTS WITH RELAPSED OR REFRACTORY AML
EHA Library, Anne Kranich, 101346
IN VITRO-GENERATED MYELOID-DERIVED SUPPRESSOR CELLS (MDSC) PREVENT MURINE GRAFT-VERSUS-HOST DISEASE (GVHD) BY INDUCING TYPE 2 T CELLS WITHOUT DISABLING ANTI-TUMOR CYTOTOXICITY
EHA Library, Gudrun Strauss, 103059
OVEREXPRESSION OF ARGINASE AND PROK-2 MAKES NEUTROPHILS OF MULTIPLE MYELOMA DYSFUNCTIONAL AND IMMUNOSUPPRESSIVE
EHA Library, Alessandra Romano, 103188
A LONGITUDINAL PROSPECTIVE STUDY EVALUATING THE EFFECTS OF ELTROMBOPAG (EPAG) TREATMENT ON BONE MARROW (BM) IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA: FINAL ANALYSIS
EHA Library, Uwe Platzbecker, 103062
GENOMIC AND DRUG RESPONSE PROFILING OF FATAL TCF3-HLF-POSITIVE PEDIATRIC ACUTE LYMPHOBLASTICLEUKEMIA IDENTIFIES RECURRENT MUTATION PATTERNS AND NOVEL THERAPEUTIC OPTIONS
EHA Library, Jean-Pierre Bourquin, 103182
PATIENTS WITH HEAVILY PRETREATED DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) WHO RESPOND TO ORAL SELINEXOR THERAPY SHOW PROLONGED SURVIVAL: UDPATED PHASE 1 RESULTS
EHA Library, John Kuruvilla, 103169
REGULATORY NETWORK GATA1-MEDIATED ON SEC23B GENE IN ERYTHROID CELLS
EHA Library, Roberta Russo, 103152
BCR-ABL LEVELS AT LANDMARK TIMEPOINTS BETWEEN 1-3 YEARS OF IMATINIB ARE PREDICTIVE OF TIME TO A DEEP MOLECULAR RESPONSE AND CAN GUIDE THERAPY SWITCH DECISIONS WHERE TKI DISCONTINUATION IS THE GOAL
EHA Library, Susan Branford, 103075
DASATINIB (DAS) IN COMBINATION WITH CHEMOTHERAPY AND AS MAINTENANCE IN CORE-BINDING FACTOR (CBF) ACUTE MYELOID LEUKEMIA (AML): A PHASE IB/IIA STUDY OF THE GERMAN-AUSTRIAN AML STUDY GROUP (AMLSG)
EHA Library, Peter Paschka, 103087
A PHASE 2, DOSE-FINDING STUDY OF SOTATERCEPT (ACE-011) IN PATIENTS (PTS) WITH LOWER-RISK MYELODYSPLASTIC SYNDROMES (MDS) AND ANEMIA REQUIRING TRANSFUSION
EHA Library, Rami S. Komrokji, 103078
SPIRIT 2: AN NCRI RANDOMISED STUDY COMPARING DASATINIB WITH IMATINIB IN PATIENTS WITH NEWLY-DIAGNOSED CHRONIC MYELOID LEUKAEMIA ? 2 YEAR FOLLOW UP
EHA Library, Stephen O'Brien, 103232
MANAGEMENT AND OUTCOME OF PRIMARY CNS LYMPHOMA AT FIRST RELAPSE/PROGRESSION: ANALYSIS OF 256 PATIENTS FROM THE FRENCH LOC NETWORK
EHA Library, Sophie Langner-Lemercier, 103054
DEREGULATION OF SNO-RNAS IN THE GENOMICALLY IMPRINTED PRADER-WILLI LOCUS IN ERG-RELATED PEDIATRIC B CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Library, Elena Vendramini, 103228
A COMPARISON OF DAUNORUBICIN/ARA-C VERSUS DAUNORUBICIN/CLOFARABINE AS INDUCTION TREATMENT IN OLDER PATIENTS WITH AML AND HIGH RISK MDS: LONG TERM RESULTS OF THE UK NCRI AML16 TRIAL IN 806 PATIENTS.
EHA Library, Nigel Russell, 103226
IMMUNOSUPPRESSION BY MESENCHYMAL STROMAL CELLS DERIVED FROM HUMAN INDUCED PLURIPOTENT STEM CELLS : EVALUATION IN AN AGVHD MODEL
EHA Library, Clémence Roux, 103167
DISSECTING THE CONTRIBUTION OF UNREGULATED MACROPHAGE IRON RECYCLING AND DIETARY IRON UPTAKE IN GENERATING SYSTEMIC IRON OVERLOAD
EHA Library, Sandro Altamura, 103118
CLINICAL CHARACTERSTICS AND RISK FACTORS OF INTRACRANIAL HAEMORRHAGE IN PATIENTS FOLLOWING ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION
EHA Library, Xiaohui Zhang, 103100
LUSPATERCEPT INCREASES HEMOGLOBIN AND REDUCES TRANSFUSION BURDEN IN PATIENTS WITH LOW OR INTERMEDIATE-1 RISK MYELODYSPLASTIC SYNDROMES (MDS): PRELIMINARY RESULTS FROM THE PHASE 2 PACE-MDS STUDY
EHA Library, Uwe Platzbecker, 103098
USEFULNESS OF TARGETED NEXT-GENERATION SEQUENCING IN INHERITED PLATELET DISORDERS WITH UNSPECIFIC PHENOTYPE
EHA Library, Jose Maria Bastida Bermejo, 103080
A COMPARISON OF LIMITED CONSOLIDATION CHEMOTHERAPY THERAPY OR NOT, AND DEMETHYLATION MAINTENANCE OR NOT IN OLDER PATIENTS WITH AML AND HIGH RISK MDS: LONG TERM RESULTS OF THE UK NCRI AML16 TRIAL.
EHA Library, Alan Burnett, 103225
ANALYSIS OF PROGNOSTIC MARKERS IN 615 PATIENTS WITH THERAPY-RELATED MYELODYSPLASTIC SYNDROMES - ARE CURRENTLY AVAILABLE SCORING SYSTEMS SUITABLE IN THIS PATIENT GROUP?
EHA Library, Andrea Kündgen, 103215
SUBCUTANEOUS VERSUS INTRAVENOUS RITUXIMAB IN COMBINATION WITH CHOP FOR PREVIOUSLY UNTREATED DIFFUSE LARGE B-CELL LYMPHOMA: EFFICACY AND SAFETY RESULTS FROM THE PHASE IIIB MABEASE STUDY
EHA Library, Pieternella (Elly) Lugtenburg, 103114
CENTRAL NERVOUS SYSTEM ACUTE LYMPHOBLASTIC LEUKEMIA IS MEDIATED BY VASCULAR ENDOTHELIAL GROWTH FACTOR PROVIDING A NOVEL TARGET FOR DIRECTED THERAPY
EHA Library, Vera Muench, 103116
LONG-TERM OUTCOME OF ALTERNATING NILOTINIB 400 MG TWICE DAILY AND IMATINIB 400 MG ONCE DAILY AS FIRST-LINE TREATMENT OF CHRONIC MYELOID LEUKEMIA: A PHASE 2 STUDY OF THE GIMEMA CML WORKING PARTY
EHA Library, Gabriele Gugliotta, 103206
ADDITIONAL PROGNOSTIC VALUE OF CIRCULATING MIR-16 EXPRESSION OVER THE USUAL PROGNOSTIC PARAMETERS IN MULTIPLE MYELOMA PATIENTS
EHA Library, Alberto Rocci, 103196
FUNCTIONAL CHARACTERIZATION OF NOVEL ABCB6 MUTATIONS AND THEIR CLINICAL IMPLICATIONS IN FAMILIAL PSEUDOHYPERKALEMIA.
EHA Library, Immacolata Andolfo, 103150
MIR-153-3P, A NEW BIO-TARGET, IS INVOLVED IN THE PATHOGENESIS OF ACUTE GRAFT-VERSUS-HOST DISEASE THROUGH THE REGULATION OF INDOLEAMINE-2,3-DIOXYGENASE
EHA Library, Xiaosu Zhao, 103139
THE PRESENCE OF GENOMIC IMBALANCES IS ASSOCIATED WITH WORSE OUTCOME IN PATIENTS WITH BURKITT LYMPHOMA TREATED WITH DOSE-INTENSIVE CHEMOTHERAPY INCLUDING RITUXIMAB
EHA Library, Jesús MHernández-Rivas, 103082
CLINICAL AND MOLECULAR PREDICTORS OF RESPONSE TO ERYTHROPOIESIS STIMULATING AGENTS (ESA) IN LOWER RISK MDS PATIENTS
EHA Library, Sophie Park, 103058
EXPRESSION LEVELS OF CD38 AND COMPLEMENT INHIBITORY PROTEINS CD55 AND CD59 PREDICT RESPONSE TO DARATUMUMAB IN MULTIPLE MYELOMA
EHA Library, Lotte van der Wagen, 103222
COMPOSITE INDEX FOR RISK PREDICTION IN RELAPSED CHILDHOOD ACUTE LYMPHOBLASTIC LEUKAEMIA
EHA Library, Anthony Moorman, 103109
AN INNOVATIVE HUMANIZED MOUSE MODEL TO INVESTIGATE THE INTERPLAY BETWEEN IMMUNE SYSTEM AND ACUTE MYELOID LEUKEMIA IN ALLOGENEIC HSCT
EHA Library, Giacomo Oliveira, 103214
ANALYSIS OF TREATMENT AND OUTCOME DATA OF 2904 PATIENTS FROM THE EUTOS POPULATION-BASED REGISTRY
EHA Library, Verena Hoffmann, 103127
HEME AND IRON CONTROL OF MACROPHAGE PLASTICITY IS PREVENTED BY THE HEME SCAVENGER HEMOPEXIN AND THE IRON CHELATOR DFO: LESSON FROM SICKLE CELL ANEMIA.
EHA Library, Francesca Vinchi, 103133
CLINICAL OUTCOME IN OLDER AML PATIENTS NOT FIT FOR INTENSIVE CHEMOTHERAPY: RESULTS OF THE POPULATION-BASED AMLSG-BIO (NCT01252485) REGISTRY STUDY OF THE GERMAN-AUSTRIAN AML STUDY GROUP
EHA Library, Richard Schlenk, 103168
BLEEDING RISK OF SURGERY IN PATIENTS WITH INHERITED PLATELET FUNCTION DISORDERS (IPFD): OUTCOME OF 389 SURGERIES IN 205 PATIENTS
EHA Library, PAOLO GRESELE, 103165
ABERRANT EXPRESSION OF THE STEM CELL MICRORNA-126 INDUCES B CELL MALIGNANCY
EHA Library, Silvia Nucera, 103086
DOWN-REGULATED BETA2-GPI IS ASSOCIATED WITH A REDUCED ABILITY TO MITIGATE COMPLEMENT ACTIVATION BY INHIBITING JNK/BID-DEPENDENT PLATELET DESTRUCTION IN THE PATHOGENESIS OF IMMUNE THROMBOCYTOPAENIA
EHA Library, Xiaohui Zhang, 103105
CONTINUED IMPROVEMENT IN SURVIVAL OF ACUTE MYELOID LEUKEMIA PATIENTS AND AN APPLICATION OF THE LOSS IN EXPECTATION OF LIFE
EHA Library, Åsa Derolf, 103219
EXOME SEQUENCING POINTS TO DIFFERENCES IN GENETIC INSTABILITY LEVEL IN MGUS COMPARED TO MM
EHA Library, Aneta Mikulasova, 103212
EFFICACY AND SAFETY OF FRONTLINE NILOTINIB IN 1089 EUROPEAN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENEST1ST FINAL ANALYSIS
EHA Library, Andreas Hochhaus, 103063
TP-0184 LOWERS HEPCIDIN LEVELS AND IS A POTENTIAL THERAPEUTIC FOR ANEMIA OF CHRONIC DISEASE
EHA Library, Steven Warner, 103178
PROGRESSIVE ANEMIA CAN BE DETECTED MORE THAN 2 YEARS PRIOR TO THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME: RESULTS FROM THE PRIMARY CARE SETTING IN DENMARK
EHA Library, Jakob Werner Hansen, 103126
THE B CELL RECEPTOR SIGNALING OUTPUT IN BURKITT?S LYMPHOMA IS GENOTYPE-SPECIFIC AND IMPACTS SENSITIVITY TOWARDS BCR SIGNALING INHIBITORS
EHA Library, Thomas Oellerich, 103128
LEUKEMIA RELAPSES AFTER ALLOGENENIC HSCT DISPLAY A DISTINCTIVE IMMUNE-RELATED SIGNATURE, WITH FUNCTIONALLY RELEVANT ALTERATIONS IN HLA CLASS II ANTIGEN PRESENTATION AND T CELL COSTIMULATION
EHA Library, Cristina TOFFALORI, 103154
Haematologica Celebration Session: Making blood: the niche in health and disease
EHA Library, David Scadden, 103641
CAR-T Cells
EHA Library, Carl June, 103664
Iron: a global issue in hematology
EHA Library, Clara Camaschella, 103663
Jean Bernard Lifetime Achievement Award: Acceptance Speech
EHA Library, Volker Diehl, 103671
UPDATED RESULTS OF A MULTICENTER PHASE I/IB STUDY OF CTLA4 BLOCKADE WITH IPILIMUMAB FOR RELAPSED HEMATOLOGIC MALIGNANCIES AFTER ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
EHA Library, Matthew Davids, 103200
CLINICAL ACTIVITY OF ERY001 (ERYTHROCYTE ENCAPSULATED L-ASPARAGINASE) IN COMBINATION WITH COOPRALL REGIMEN IN PHASE 3 RANDOMIZED TRIAL IN PATIENTS WITH RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Library, Yves Bertrand, 103145
ADHERENCE AND DOSE INTENSITY FOLLOWING ADMINISTRATION OF THE IBRUTINIB 420 MG DOSE IN PATIENTS WITH PREVIOUSLY TREATED CLL
EHA Library, Ulrich Jäger, 103137
PHASE 2 STUDY OF DARATUMUMAB MONOTHERAPY IN PATIENTS WITH ?3 LINES OF PRIOR THERAPY OR DOUBLE REFRACTORY MULTIPLE MYELOMA: 54767414MMY2002 (SIRIUS)
EHA Library, Sagar Lonial, 103136
UCART19, AN ALLOGENEIC 'OFF-THE-SHELF' ADOPTIVE T-CELL IMMUNOTHERAPY AGAINST CD19+ B-CELL LEUKEMIAS
EHA Library, Julianne Smith, 103230
OUTCOMES OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) IN PATIENTS WITH MYELOFIBROSIS (MF) EXPOSED TO JAK1/2 INHIBITORS
EHA Library, Mohamed Shanavas, 103073
RUNX1 MUTATION AND/OR DISRUPTION OF THE C-TERMINAL DOMAIN MAY BE CRITICAL FOR CHRONIC MYELOID LEUKAEMIA (CML) BLAST CRISIS TRANSFORMATION
EHA Library, Lihui Wang, 103066
MICRORNA EXPRESSION BASED OUTCOME PREDICTION IN AML ? CROSS-PLATFORM INTEGRATIVE ANALYSES LEAD THE WAY TO NOVEL INSIGHTS
EHA Library, Velizar Shivarov, 103124
A HYPOPHOSPHORYLATED AUTOANTIGEN IS THE FIRST MOLECULARLY DEFINED RISK FACTOR AND A DOMINANT ANTIGENIC TARGET / STIMULUS OF THE B-CELL RECEPTOR FROM ABC-TYPE DLBCL
EHA Library, Michael Pfreundschuh, 103187
EXCELLENT LONG-TERM PROGNOSIS OF IMATINIB-TREATED FIP1L1-PDGFRA POSITIVE EOSINOPHILIA-ASSOCIATED MYELOPROLIFERATIVE NEOPLASM IN CHRONIC OR BLAST PHASE
EHA Library, Georgia Metzgeroth, 103077
ALLOGENEIC TRANSPLANTATION FOR MYELOFIBROSIS: HIGH DOSE INTENSITY AND EARLY DISEASE STATE ARE FAVORABLE PROGNOSTIC FACTORS.
EHA Library, Uday Popat, 103097
TARGETING EPITHELIAL TO MESENCHYMAL TRANSITION (EMT) THROUGH CXCR4 BLOCKADE IN MULTIPLE MYELOMA
EHA Library, Aldo Roccaro, 103406
EFFECT OF AGE ON EFFICACY AND SAFETY OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA RECEIVING LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE (RD): THE FIRST TRIAL
EHA Library, Cyrille Hulin, 103067
MUTATION ANALYSIS OF EPIGENETIC MODIFIERS IN CHRONIC PHASE CML USING NEXT GENERATION SEQUENCING
EHA Library, Georgios Nteliopoulos, 103229
ALLOGENIC ADOPTIVE IMMUNOTHERAPY OF ACUTE MYELOID LEUKEMIA (AML) BY TARGETING CD123 WITH CAR T-CELLS
EHA Library, Roman Galetto, 103221
GENOMIC DNA BREAKPOINTS IN MLL AND TRANSLOCATION PARTNER GENES IN A LARGE COHORT OF INFANTS WITH ACUTE LEUKEMIA
EHA Library, Grigory Tsaur, 103220
UTILIZING EXOSOMES AS INNOVATIVE MICRORNA BIOMARKERS AND TARGETED DRUG-DELIVERY VEHICLES IN ACUTE MYELOID LEUKEMIA
EHA Library, Rose McGlauflin, 103115
EARLY CLINICAL ACTIVITY AND PHARMACODYNAMIC EFFECTS OF DUVELISIB, A PI3K-DELTA,GAMMA INHIBITOR, IN PATIENTS WITH TREATMENT-NA
EHA Library, Susan O'Brien, 103207
BCL6 AND EZH2 COOPERATE TO ASSEMBLE NON-CANONICAL PRC1-BCOR COMPLEX TO MEDIATE GERMINAL CENTER FORMATION AND PROMOTE LYMPHOMAGENESIS BY REPRESSING BIVALENT CHROMATIN DOMAINS
EHA Library, Wendy Beguelin, 103199
A THERAPEUTIC NKT CELL ADJUVANT-BASED VACCINE INDUCES AN EFFECTIVE ANTITUMORAL IMMUNE RESPONSE IN B-CELL LYMPHOMA
EHA Library, Laura Escribà, 103143
HUMAN ATRIAL NATRIURETIC PEPTIDE (HANP) THERAPY IN THE EARLY PHASE AFTER ALLOGENEIC STEM CELL TRANSPLANT (ALLO-SCT) PREVENTS DEVELOPMENT OF CHRONIC KIDNEY DISEASE (CKD): RESULTS FROM A PHASE 2 STUDY
EHA Library, Hiroaki Shimizu, 103070
JAM-C: A NEW LEUKEMIC STEM CELL BIOMARKER IN ACUTE MYELOID LEUKEMIA
EHA Library, Maria De Grandis, 103065
THE QUADRUPLET COMBINATION OF CARFILZOMIB, CYCLOPHOSPHAMIDE, LENALIDOMIDE, AND DEXAMETHASONE IS SAFE AND WELL TOLERATED AS INDUCTION THERAPY FOR NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE, MYELOMA PATIENTS.
EHA Library, Charlotte Pawlyn, 103110
HIGH THROUGHPUT SEQUENCING AS A MEASURE OF EARLY RESPONSE TO THERAPY IN CHILDHOOD ALL
EHA Library, Ilan Kirsch, 103135
RUXOLITINIB (RUX) IN COMBINATION WITH 5-AZACYTIDINE (AZA) AS THERAPY FOR PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
EHA Library, Naval Daver, 103158
IDENTIFICATION OF DIFFERENTIALLY METHYLATED DISTANT ENHANCERS RELATED TO ABERRANT EXPRESSION OF SOX11 IN MANTLE CELL LYMPHOMA
EHA Library, Renée Beekman, 103148
CORRECTION OF MUTATIONS OF THE EPIGENETIC MODIFIER ASXL1 IN MYELOID LEUKEMIA CELLS BY CRISPR/CAS9 GENOME EDITING
EHA Library, Simona Valletta, 103146
TGR-1202, A NOVEL ONCE DAILY PI3K-DELTA INHIBITOR, DEMONSTRATES CLINICAL ACTIVITY WITH A FAVORABLE SAFETY PROFILE, LACKING HEPATOTOXICITY, IN PATIENTS WITH CLL AND B-CELL LYMPHOMA
EHA Library, Howard A.Burris, 103192
LEUKAEMIA-ASSOCIATED SOMATIC MUTATIONS DRIVE DISTINCT PATTERNS OF AGE-RELATED CLONAL HAEMOPOIESIS
EHA Library, Thomas McKerrell, 103060
GENERATION OF EBV-SPECIFIC AND EBV-SPECIFIC, TCR-REPROGRAMMED HUMAN CD8+ CYTOTOXIC T LYMPHOCYTES WITH STEM CELL MEMORY AND CENTRAL MEMORY PROPERTIES BY MODULATING GLYCOLYTIC T CELL METABOLISM
EHA Library, Udo Hartwig, 103117
RUXOLITINIB VERSUS BEST AVAILABLE THERAPY IN PATIENTS WITH POLYCYTHEMIA VERA: 80-WEEK FOLLOW-UP FROM THE RESPONSE TRIAL
EHA Library, Jean-Jacques Kiladjian, 103108
EFFECT OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA BY LINE OF THERAPY: INTERIM RESULTS FROM THE PHASE 3 ASPIRE STUDY
EHA Library, Meletios Dimopoulos, 103134
THE PREDICTIVE STRENGTH OF NEXT GENERATION SEQUENCING MINIMAL RESIDUAL DISEASE DETECTION FOR RELAPSE COMPARED WITH CURRENT METHODS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Library, Michaela Kotrová, 103071
MYC-MAX HETERODYMER POSITIVELY REGULATES BCR AND BCR/ABL EXPRESSION
EHA Library, Vera Magistroni, 103142
NPM-ALK MIMICS THYMIC PRE-T CELL RECEPTOR (TCR) EXPANSION BUT REQUIRES TRANSIENT TCR EXPRESSION FOR THYMIC EGRESS AND PERIPHERAL ANAPLASTIC LARGE CELL LYMPHOMA DEVELOPMENT
EHA Library, Amélie Trinquand, 103155
KIR2DS4 AND ITS VARIANT KIR1D ARE ASSOCIATED WITH AGVHD, CMV AND OS AFTER SIBING RELATED HLA MATCHED TRANSPLANTATION FOR PATIENTS WHOSE DONORS BELONG TO KIR GENE HAPLOTYPE A
EHA Library, Xiaojin Wu, 103052
Mycosis Fungoides: Diagnostic Considerations
EHA Library, Patty Jansen, 103613
DNMT3A MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML): MONITORING OF MINIMAL RESIDUAL DISEASE (MRD). A STUDY OF THE AML STUDY GROUP (AMLSG).
EHA Library, Verena I Gaidzik, 103190
SECOND GENERATION TYROSINE KINASE INHIBITORS SUPPRESS THE CIP2A/C-MYC/E2F1 PATHWAY
EHA Library, Richard Clark, 103121
VENETOCLAX (ABT-199 / GDC-0199) COMBINED WITH RITUXIMAB INDUCES DEEP RESPONSES IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
EHA Library, Andrew W Roberts, 103125
OUTCOMES OF GENE THERAPY FOR ?-THALASSEMIA MAJOR AND SEVERE SICKLE DISEASE VIA TRANSPLANTATION OF AUTOLOGOUS HEMATOPOIETIC STEM CELLS TRANSDUCED EX VIVO WITH A LENTIVIRAL BETA GLOBIN VECTOR
EHA Library, Marina Cavazzana-Calvo, 103175
TYROSINE KINASE FUSION GENES IN PEDIATRIC BCR-ABL1-LIKE ACUTE LYMPHOBLASTIC LEUKEMIA
EHA Library, Judith Boer, 103107
THE LANDSCAPE OF SOMATIC ALTERATIONS IN ADULT T-CELL LEUKEMIA/LYMPHOMA
EHA Library, Keisuke Kataoka, 103057
DROPLET DIGITAL PCR FOR DNMT3A AND IDH1/2 MUTATIONS TO IMPROVE EARLY DETECTION OF ACUTE MYELOID LEUKEMIA RELAPSE AFTER ALLOGENEIC HSCT
EHA Library, Chiara Brambati, 103151
RESULTS FROM TWO PHASE 3 STUDIES OF POST-TRANSPLANT BORTEZOMIB (BTZ) CONSOLIDATION VS OBSERVATION (OBS) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
EHA Library, Hermann Einsele, 103092
RISK FACTORS FOR THROMBOHEMORRHAGIC AND TRANSFORMATION EVENTS IN 3649 HIGH-RISK PATIENTS WITH ESSENTIAL THROMBOCYTHEMIA: RESULTS FROM THE PROSPECTIVE LONG-TERM OBSERVATIONAL EXELS STUDY
EHA Library, Gunnar Birgegard, 103157
Novel Biological Insights In Primary Cutaneous T-cell Lymphomas Other Than Mycosis Fungoides
EHA Library, Leticia Quintanilla de Fend, 103612
Therapeutic principles in primary cutaneous T-cell lymphomas
EHA Library, Emmanuella Guenova, 103614

Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.



Google Analytics is used for user behavior tracking/reporting. Google Analytics works in parallel and independently from MLG’s features. Google Analytics relies on cookies and these cookies can be used by Google to track users across different platforms/services.



{$cookies-google-tag-manager-description}


Save Settings